Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma

What Was Tested

The paper reports a study of Octreotide, published as a clinical trial.

Therefore, the aim of their study was to assess the clinical value of two technetium-99m-labeled peptides, a new gastrin analog, the EDDA/HYNIC-(D)Glu-octagastrin and a somatostatin analog, EDDA/HYNIC-Tyr(3)-octreotide (EDDA/HYNIC-TOC) for scintigraphy in patients with MTC to detect recurrences and metastases and select patients for peptide receptor radiotherapy.

Why It Was Studied

Somatostatin and gastrin receptors are overexpressed in medullary thyroid carcinoma (MTC) cells; hence, both of them are potential targets for peptide receptor scintigraphy and radiotherapy.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.

Thirty (30) patients, 20 females and 10 males, 22-83 years of age (mean, 52.7) with the diagnosis of MTC in different stages of the disease (preoperative, postsurgery, remission, recurrence, or metastatic disease) were included in this study.

Before surgery, in all patients serum calcitonin concentrations were elevated.

How the Study Was Run

The diagnosis of MTC was confirmed in all cases by histopathology of the removed tumor and immunohistochemical staining giving positive reactions for calcitonin and chromogranin A.

Imaging studies using (99m)Tc-EDDA/HYNIC-TOC and a new minigastrin analog, (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin, were performed in each patient and the results compared with each other and with other imaging methods.

Scans of the whole body, head, neck, and chest were performed 2 and 4 hours after injections of the tracer, 500-600 MBq in each case, using a double-head Varicam (Elscint, Israel) gamma camera.

What Was Measured

The subject headings attached to it are Carcinoma, Medullary, Edetic Acid, Gastrins, Hydrazines, Indium Radioisotopes, Mice and Mice, Inbred BALB C.

What This Means in Plain Language

This is a clinical trial of Octreotide.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (Cancer biotherapy & radiopharmaceuticals), a journal based in United States.

More context: the Octreotide compound page, all human trials.